Mechanotransduction and Chemoresistance: Viscosity-Driven Upregulation of P-gp in Tumor Cells

Study Background and Research Question

Chemoresistance remains a significant barrier to the efficacy of cancer chemotherapy, with transporter-mediated drug disposition frequently undermining therapeutic outcomes. While the role of the tumor microenvironment (TME)—including hypoxia, acidity, and stromal interactions—in promoting drug resistance is well established, mechanical features such as extracellular fluid viscosity have received less attention. Notably, the viscosity of tumor interstitial fluid can be substantially higher (~8 cP) than that of normal tissues (~0.7 cP), yet its functional consequences on cellular drug resistance have been unclear. The reference study (Zhou et al., 2026) addresses the central question: Can high extracellular viscosity act as a mechanical cue sensed by cancer cells, ultimately driving chemoresistance through mechanobiological pathways?

Key Innovation from the Reference Study

The work by Zhou et al. provides a mechanistic framework directly linking high-viscosity microenvironments to increased chemoresistance. The study demonstrates, for the first time, that elevated viscosity not only alters cellular biomechanics but also upregulates P-glycoprotein (P-gp/ABCB1) expression through a specific cascade involving cell membrane tension, TRPV4 activation, and YAP nuclear translocation. This mechanotransduction axis translates a purely biophysical stimulus—viscous tumor fluid—into a transcriptional program that enhances the efflux of chemotherapeutic drugs, such as doxorubicin, and reduces their cytotoxic efficacy.

Methods and Experimental Design Insights

The researchers employed a combination of biophysical assays, molecular biology techniques, and functional drug resistance measurements to dissect the pathway:

• Cell cultures were exposed to media with physiologically relevant viscosity (up to 8 cP), closely mimicking the tumor milieu.
• Atomic force microscopy and fluorescence lifetime imaging were used to quantify cell membrane tension and cytoskeletal remodeling.
• P-gp expression levels were measured via qPCR and Western blotting, while functional resistance to doxorubicin was assessed using cell viability assays.
• Mechanistic links were interrogated through pharmacological inhibition of TRPV4 and YAP, as well as calcium imaging and nuclear localization studies.

This multi-level approach allowed the authors to trace the sequence from external mechanical force (high viscosity) to intracellular signaling (TRPV4 activation, Ca²⁺ influx, YAP nuclear translocation) and finally to functional outcomes (P-gp upregulation and drug resistance).

Core Findings and Why They Matter

Several key findings emerge from the reference study:

• High extracellular viscosity directly enhances the F-actin/vinculin cytoskeletal network and increases water influx via NHE1/AQP1, resulting in elevated membrane tension.
• This increased tension activates the mechanosensitive ion channel TRPV4, leading to higher intracellular Ca²⁺ levels.
• TRPV4 activation suppresses the Hippo pathway and promotes nuclear translocation of YAP, a transcriptional co-activator.
• Nuclear YAP increases the transcription of its target genes, including CTGF, CYR61, and critically, P-gp (ABCB1), thereby enhancing efflux of chemotherapeutics and promoting chemoresistance.
• Importantly, pharmacological or genetic inhibition of YAP abrogates the viscosity-induced increase in P-gp and chemoresistance, confirming the pathway’s centrality.

These findings underscore the need to consider not only biochemical but also mechanical properties of the TME in drug resistance research. The demonstration that physical cues like viscosity can drive transporter upregulation expands the mechanobiological paradigm and identifies new potential interventions, such as disrupting mechanosensitive signaling or directly targeting P-gp.

Comparison with Existing Internal Articles

These insights resonate with and extend the themes explored in several internal resources. For example, "High Viscosity Drives Chemoresistance via P-gp Upregulation" and "High Viscosity Drives P-gp-Mediated Chemoresistance in Tumors" both highlight the role of extracellular viscosity and mechanotransduction in the upregulation of ABC transporters. However, the reference study adds mechanistic depth by identifying the TRPV4-YAP axis as a critical mediator. Furthermore, internal articles such as "Tariquidar (XR9576): Overcoming Chemoresistance via Mechanobiology" bridge these insights to applied workflows, discussing how selective P-gp inhibitors like Tariquidar can be used to experimentally dissect and overcome high-viscosity-induced resistance in vitro and in vivo. The integration of biophysical and pharmacological approaches represents a promising trend in cancer chemoresistance studies.

Limitations and Transferability

While the reference study provides compelling evidence for the mechanobiological regulation of P-gp in response to elevated viscosity, several limitations warrant consideration. Most experiments were performed in vitro, using controlled increases in media viscosity and established cancer cell lines. While these models capture key aspects of the tumor microenvironment, in vivo validation is needed to confirm the relevance and specificity of the TRPV4-YAP-P-gp pathway in the context of complex tumors. Additionally, the precise role of other ABC transporters and the long-term effects of modulating viscosity remain to be elucidated. Thus, while the findings are highly suggestive, direct translation to clinical or animal models will require further study.

Protocol Parameters

• High-viscosity media preparation: Adjust cell culture medium to ~8 cP using inert viscosity modifiers (e.g., high-molecular-weight dextran); confirm viscosity via viscometry before use.
• P-gp expression analysis: Assess ABCB1 mRNA by qPCR and P-gp protein levels by Western blotting after 48-72 h exposure to high-viscosity media.
• Functional drug resistance assay: Treat cells with standard concentrations of doxorubicin following viscosity exposure; measure cell viability after 24-48 h using resazurin or MTT assays.
• Mechanistic inhibition: Use selective TRPV4 inhibitors (e.g., GSK2193874) and YAP transcriptional inhibitors (e.g., verteporfin) to dissect pathway contributions; apply inhibitors 1-2 h before viscosity treatment.
• Positive control for transporter inhibition: Apply XR9576 (Tariquidar) at 100–500 nM to confirm P-gp-mediated efflux function, as recommended in established protocols.

Research Support Resources

Researchers seeking to implement or extend these workflows can utilize Tariquidar (SKU A8208), a potent, selective noncompetitive P-gp inhibitor. Tariquidar has been validated for use in high-viscosity, chemoresistant models to probe ABC transporter inhibition and enhance drug accumulation in vitro and in animal studies. For preparation and storage guidelines, refer to the product documentation or see applied protocols in internal research articles. As always, Tariquidar is for research use only and not for diagnostic or therapeutic applications.